AMY ROTHSTEIN: Open Payments
NPI 1871218115 · ROCKVILLE, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,475 in 53 payments from 19 companies in 2025. Trend: 2023 $768 · 2024 $2,230 · 2025 $1,475
Food & beverage: $1,449Education: $26
| Company | Payments | Amount |
|---|---|---|
| Sumitomo Pharma America, Inc. | 12 | $260 |
| Janssen Biotech, Inc. | 5 | $210 |
| PFIZER INC. | 6 | $158 |
| PROGENICS PHARMACEUTICALS, INC. | 5 | $151 |
| Bayer Healthcare Pharmaceuticals Inc. | 4 | $112 |
| Janssen Pharmaceuticals, Inc | 3 | $78 |
| Novartis Pharmaceuticals Corporation | 2 | $65 |
| Dendreon Pharmaceuticals LLC | 2 | $57 |
| UROGEN PHARMA, INC. | 2 | $51 |
| Boston Scientific Corporation | 2 | $49 |
Products named: ERLEADA, XTANDI, ORGOVYX, PYLARIFY, Nubeqa, GEMTESA, RYBREVANT, PLUVICTO.
Industry payments across MD — which companies pay providers there.
